MediWound Ltd (M8W) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MediWound Ltd (M8W) has a cash flow conversion efficiency ratio of -0.069x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.02 Million ≈ $-3.53 Million USD) by net assets (€43.63 Million ≈ $51.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of MediWound Ltd to measure how many days the company can operate on defensive assets alone.
MediWound Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how MediWound Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MediWound Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MediWound Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Maiquer Group Co Ltd
SHE:002719
|
-0.073x |
|
Hostelworld Group PLC
IR:HSW
|
0.076x |
|
Taylor Devices Inc
NASDAQ:TAYD
|
0.013x |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IS:BIGTK
|
-0.020x |
|
CB Financial Services Inc
NASDAQ:CBFV
|
0.019x |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
|
0.062x |
|
SC II Acquisition Corp. Class A ordinary share
NASDAQ:SCII
|
14.005x |
|
Jaeren Sparebank
OL:JAREN
|
-0.105x |
Annual Cash Flow Conversion Efficiency for MediWound Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of MediWound Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see M8W stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €43.63 Million ≈ $51.01 Million |
€-16.12 Million ≈ $-18.85 Million |
-0.369x | +15.51% |
| 2024-12-31 | €31.15 Million ≈ $36.42 Million |
€-13.62 Million ≈ $-15.93 Million |
-0.437x | -32.03% |
| 2023-12-31 | €31.59 Million ≈ $36.94 Million |
€-10.46 Million ≈ $-12.23 Million |
-0.331x | +69.58% |
| 2022-12-31 | €10.91 Million ≈ $12.76 Million |
€-11.88 Million ≈ $-13.89 Million |
-1.089x | -155.96% |
| 2021-12-31 | €-4.58 Million ≈ $-5.36 Million |
€-8.92 Million ≈ $-10.42 Million |
1.946x | +305.23% |
| 2020-12-31 | €7.27 Million ≈ $8.50 Million |
€-6.89 Million ≈ $-8.06 Million |
-0.948x | -273.51% |
| 2019-12-31 | €15.17 Million ≈ $17.73 Million |
€8.29 Million ≈ $9.69 Million |
0.546x | +140.34% |
| 2018-12-31 | €8.97 Million ≈ $10.49 Million |
€-12.15 Million ≈ $-14.21 Million |
-1.355x | +20.80% |
| 2017-12-31 | €9.62 Million ≈ $11.25 Million |
€-16.45 Million ≈ $-19.24 Million |
-1.710x | +19.18% |
| 2016-12-31 | €7.77 Million ≈ $9.08 Million |
€-16.45 Million ≈ $-19.23 Million |
-2.116x | -- |
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn cen… Read more